School of Bioengineering Sciences and Research, MIT Arts, Design and Technology University, Rajbaugh Campus, Loni Kalbhor, Pune, Maharashtra, 412201, India.
Med Oncol. 2023 Nov 28;41(1):2. doi: 10.1007/s12032-023-02229-w.
Breast cancer stands as a prominent contributor to cancer-related fatalities among women globally, characterized by an unfavorable prognosis, low survival rates, and its conventional treatment approach involving chemotherapy. Doxorubicin (DOXO) represents a potent anti-tumor agent widely employed in combating breast cancer. Regrettably, a substantial proportion of patients eventually develop resistance to DOXO treatment, elevating the risk of relapse and adverse clinical outcomes. Omega-3 polyunsaturated fatty acids (n-3 PUFAs), recognized as essential components of the human diet, have exhibited considerable promise in targeting malignant cells, initiating apoptosis, and impeding tumor proliferation and metastatic dissemination. Combining these nutritional supplements, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), with DOXO presents a compelling strategy to augment treatment efficacy. The present study was conducted employing a breast cancer cell line, MCF-7, to assess the synergistic potential of DHA, EPA, and DOXO. Remarkably, the combination treatment yielded a substantial increase in cytotoxicity compared to the administration of DOXO alone. Furthermore, an enhancement in the suppression of metastasis was evident in the combination treatment relative to the exclusive use of DOXO. Cell cycle analysis unveiled that cells subjected to the combination treatment exhibited a more pronounced arrest in the G1 phase, signifying the combination's heightened effectiveness in impeding cell progression into the doubling phase. Collectively, the amalgamation of n-3 polyunsaturated fatty acids (n-3 PUFAs) emerges as a potent strategy for enhancing the therapeutic potential of DOXO, effectively restraining the growth and dissemination of breast cancer cells.
乳腺癌是全球女性癌症相关死亡的主要原因之一，其预后不良、生存率低，且传统的治疗方法包括化疗。多柔比星（DOXO）是一种广泛用于治疗乳腺癌的有效抗肿瘤药物。遗憾的是，相当一部分患者最终对 DOXO 治疗产生耐药性，增加了复发和不良临床结局的风险。ω-3 多不饱和脂肪酸（n-3 PUFAs）被认为是人类饮食的重要组成部分，已被证明在靶向恶性细胞、引发细胞凋亡以及抑制肿瘤增殖和转移扩散方面具有很大的潜力。将这些营养补充剂，特别是二十碳五烯酸（EPA）和二十二碳六烯酸（DHA）与 DOXO 联合使用，是提高治疗效果的一种很有前途的策略。本研究采用乳腺癌细胞系 MCF-7 来评估 DHA、EPA 和 DOXO 的协同潜力。值得注意的是，与单独使用 DOXO 相比，联合治疗显著增加了细胞毒性。此外，与单独使用 DOXO 相比，联合治疗在抑制转移方面的增强作用更为明显。细胞周期分析表明，联合处理的细胞在 G1 期表现出更为明显的阻滞，表明联合处理在阻止细胞进入倍增期方面更为有效。总之，将 n-3 多不饱和脂肪酸（n-3 PUFAs）联合使用是增强 DOXO 治疗潜力的有效策略，可以有效抑制乳腺癌细胞的生长和扩散。
